Cerebrospinal fluid glial fibrillary acidic protein provides differential diagnostic value in some forms of dementias
Date
Language
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Abstract
Background: Glial fibrillary acidic protein (GFAP) is a marker of cerebral astrogliosis and occasionally elevated in patients with dementia. GFAP in cerebrospinal fluid (CSF), is routinely requested in referrals to neurochemistry laboratories; however, its ability to differentiate dementias and diagnostic capability is unclear. Our aim was to elucidate this, using two large datasets.
Method: First, GFAP data measured since 2015 was retrieved from the database of the Clinical Neurochemistry Laboratory at the Sahlgrenska University hospital. We then cross‐referenced with the Swedish dementia registry (SveDem). Here, information on ten different diagnoses such as early onset AD (EAD [<65 years]), late onset AD (LAD [≥65 years]), Parkinson disease with dementia (PDD), vascular dementia (VaD) and frontotemporal dementia (FTD), each with specific diagnostic criteria, were retrieved.
The GFAP data was log10‐transformed, followed by an analysis of covariance (ANCOVA) and a subsequent post‐hoc Tukey’s test, with GFAP as dependent variable, diagnosis as independent variable and sex and age as covariates.
Result: In total, 1912 individuals (mean [SD] age, 71.9 [8.2] years; 52% male), were included. Lower log10‐transformed GFAP concentrations were seen in PDD (mean [SD], 2.68, [0.28] pg/mL), than in EAD, LAD, VaD and FTD; here, mean concentrations of 2.76 (0.24), 2.89 (0.23), 2.89 (0.32) and 2.76 (0.25) pg/mL were observed, respectively.
In the post hoc analysis, GFAP differentiated VaD from EAD (p<0.001). PDD concentrations were significantly different from VaD (p<0.001) and LAD (p<0.001). Further, it also differentiated FTD from VaD (p=0.006) and LAD (p=0.001).
Conclusion: CSF GFAP could on a group level help differentiate VaD from EAD, FTD and PDD. Also, it could differentiate PDD from LAD. These results bear potential clinical relevance, where clinicians in some uncertain cases could use this marker as a differential tool.
